SCOR has made a follow-on investment in BioSerenity, a French-based innovative medical technology company focused on Healthcare as a service, IoMT, artificial intelligence and real-world evidence in neurology, sleep medicine, and cardiology. BioSerenity provides remote diagnostic solutions to healthcare providers and patients in the United States, Europe and the Caribbean.
This second investment in BioSerenity pursues SCOR’s value proposition of making Life insurance more accessible and desirable by simplifying the medical underwriting process for the consumer, and by helping people to live healthier and longer lives. This has already proved effective in practice, as demonstrated by BioSerenity’s Cardiophy Check-up – an at-home underwriting tool implemented by a leading French distributor.
To deliver on its mission “to provide physicians and patients with 24/7 continuous care,” BioSerenity has built a vertically integrated business in diagnostics and monitoring. By leveraging proprietary devices and hiring technologists and expert physicians, BioSerenity enables both patients and physicians to remotely follow continuous electrophysiological signals in the fields of cardiology, neurology and sleep disorders. With a clouded layer of data and advanced algorithms, BioSerenity facilitates the process and analysis of health data.
“Bioserenity is helping to make the Life insurance purchasing process easier and less invasive by facilitating simple, at-home underwriting. This follow-on strategic investment continues our support for BioSerenity, enabling us to develop more affordable and inclusive insurance covers while helping people to diagnose and manage their health conditions through wearable technology”, said Brona Magee, Deputy CEO for Life & Health at SCOR. “We are actively helping our clients to build easy-to-buy products and improve the health outcomes of their policyholders.”